Latest Feature

Checking on Orange County's medtech climate with OCTANe's Matthew Jenusaitis

Orange County, Calif.'s most-connected man, OCTANe's Matthew Jenusaitis talks to MassDevice.com about OCTANe's 2014 Medical Device Investor Forum.

What's behind the slump in early-stage medtech investment?

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells MassDevice.com.

Kimberly-Clark readies Halyard Health medical device spinout

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

HART CEO David Green on the transformative potential for regenerative medicine

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Masimo wins $467m verdict in patent spat with Philips

October 2, 2014 by Alexander Soule

A jury delivers a $467 million verdict for Masimo in a patent infringement spat with Royal Philips over pulse oximetry technology.

Masimo wins $467m verdict in patent spat with Philips

Analyst says BSX may take CRM lead | Medtech Wall Street news for the week of September 29, 2014

October 2, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week:

Analyst: Boston Scientific could take CRM lead

September 25, 2014 by Alexander Soule

Analyst: Edwards Lifesciences' Sapien 3 poised to lead TAVI market | MassDevice.com On Call

October 2, 2014 by Brad Perriello

The Sapien 3 replacement heart valve made by Edwards Lifesciences is poised to take the lead in the market for transcatheter aortic valve implants, according to one analyst.

MASSDEVICE ON CALL — Edwards Lifesciences (NYSE:EW) is poised to take the lead in the transcatheter aortic valve market with its Sapient 3 replacement heart valve, according to Leerink Partners analyst Danielle Antalffy.

MassDevice.com +3 | The top 3 medtech stories for October 1, 2014

October 1, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

LoneStar Heart wins CE Mark for hydrogel heart implant

October 1, 2014 by Alexander Soule

LoneStar Heart wins CE Mark approval in the European Union for its Algisyl-LVR hydrogel implant, a hydrogel implant designed to treat heart failure.

LoneStar Heart wins CE Mark for hydrogel heart implant

Laguna Hills, Calif.-based LoneStar Heart said it won CE Mark approval in the European Union for its Algisyl-LVR hydrogel implant for the treatment of advanced heart failure. 

UCLA spinout NeuroSigma seeks $50m in IPO

October 1, 2014 by Alexander Soule

NeuroSigma is aiming to net as much as $50.2 million in its upcoming IPO, as the UCLA spinout develops a noninvasive system to treat epilepsy that proves resistant to drug regimens.

UCLA spinout NeuroSigma seeks $50m in IPO

NeuroSigma aims to reap as much as $50.2 million in its upcoming initial public offering for the UCLA spinout's noninvasive system to treat drug-resistant epilepsy.

Our first dive into the new Open Payments system

October 1, 2014 by MassDevice

The government's data on payments to doctors and hospitals by drug and device makers is incomplete and hard to penetrate – but here's a first look.

Our first dive into the new Open Payments system

David Sleight/ProPublica

by Charles Ornstein, ProPublica

The federal government unveiled data Tuesday detailing 4.4 million payments made to doctors and teaching hospitals by pharmaceutical and medical device companies.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp